Dr. Julie Decock

Breast cancer is the most common malignancy and is the second most common cause of cancer-related deaths among women worldwide. In Qatari women, breast cancer is the most common cancer with projections of a 60% increase in newly diagnosed cases over the next 6 years. Triple negative breast cancer represents 15-20% of breast cancer cases and is associated with advanced disease at diagnosis and poorer outcome. These patients do not benefit from endocrine or HER2-targeted therapies, mandating the need for novel therapeutic approaches. Furthermore, the molecular mechanisms underlying the aggressive behavior and poor clinical phenotype of triple negative breast cancer are not yet fully understood. Dr Decock is currently leading a project investigating the expression and role of cancer testis antigens in triple negative breast cancer, with the goal to develop a novel adoptive T cell therapeutic modality for patients with this specific type of breast tutors.


Julie Decock
Julie Decock

Dr. Julie Decock
Scientist
Back to Top